Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Travere Therapeutics Inc

TVTX
Current price
17.57 USD -0.23 USD (-1.32%)
Last closed 17.5 USD
ISIN US89422G1076
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 373 787 648 USD
Yield for 12 month +152.08 %
1Y
3Y
5Y
10Y
15Y
TVTX
21.11.2021 - 28.11.2021

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Address: 3611 Valley Centre Drive, San Diego, CA, United States, 92130

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

22.67 USD

P/E ratio

Dividend Yield

Current Year

+145 238 000 USD

Last Year

+212 018 000 USD

Current Quarter

+54 116 000 USD

Last Quarter

+41 374 000 USD

Current Year

+88 856 000 USD

Last Year

+204 426 000 USD

Current Quarter

+41 710 000 USD

Last Quarter

+39 870 000 USD

Key Figures TVTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -275 060 000 USD
Operating Margin TTM -123.9 %
PE Ratio
Return On Assets TTM -30.7 %
PEG Ratio
Return On Equity TTM -582.61 %
Wall Street Target Price 22.67 USD
Revenue TTM 177 644 000 USD
Book Value 0.2 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 68.1 %
Dividend Yield
Gross Profit TTM -31 354 000 USD
Earnings per share -4.98 USD
Diluted Eps TTM -4.98 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -82.14 %

Dividend Analytics TVTX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History TVTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:9
Payout Ratio
Last Split Date 08.11.2011
Dividend Date

Stock Valuation TVTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 7.9863
Price Sales TTM 7.7334
Enterprise Value EBITDA -5.6654
Price Book MRQ 88.5255

Financials TVTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators TVTX

For 52 weeks

5.12 USD 19.25 USD
50 Day MA 13.61 USD
Shares Short Prior Month 6 962 090
200 Day MA 9.29 USD
Short Ratio 3.02
Shares Short 8 107 720
Short Percent 11.92 %